1: Raymond S, Nicot F, Carcenac R, Jeanne N, Cazabat M, Requena M, Cuzin L, 
Delobel P, Izopet J; ANRS 145 MARIMUNO Study Group. No selection of CXCR4-using 
variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive 
maraviroc therapy. AIDS. 2016 Mar 27;30(6):965-8. doi: 
10.1097/QAD.0000000000001013. PubMed PMID: 26752281.

2: Ahmed N, Okoli C, Ainsworth J. Ineffective central nervous system HIV 
suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: 
four case reports. Int J STD AIDS. 2016 Mar;27(4):321-2. doi: 
10.1177/0956462415584486. Epub 2015 May 11. PubMed PMID: 25969439.

3: Karlsson U, Repits J, Antonsson L, Cederfjäll E, Ljungberg B, Ålenius M, 
Sabirsh A, Gisslen M, Esbjörnsson J, Jansson M. Reduced Baseline Sensitivity to 
Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe 
Immunodeficiency. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):e79-82. doi: 
10.1097/QAI.0000000000000873. PubMed PMID: 26492461.

4: Stellbrink HJ, Fevre EL, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, 
Vourvahis M, Rinehart AR, Mcfadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, 
Heera J. Once-daily maraviroc versus tenofovir/emtricitabine each combined with 
darunavir/ritonavir for initial HIV-1 treatment: 48-week results from the MODERN 
study. AIDS. 2016 Feb 5. [Epub ahead of print] PubMed PMID: 26854810.

5: Herrera C, Armanasco N, García-Pérez J, Ziprin P, Olejniczak N, Alcami J, 
Nuttall J, Shattock RJ. Maraviroc and reverse transcriptase inhibitors 
combinations as potential pre-exposure prophylaxis candidates. AIDS. 2016 Feb 5. 
[Epub ahead of print] PubMed PMID: 26854808.

6: Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. 
Maraviroc-intensified combined antiretroviral therapy improves cognition in 
virally suppressed HIV-associated neurocognitive disorder. AIDS. 2016 Feb 
20;30(4):591-600. doi: 10.1097/QAD.0000000000000951. PubMed PMID: 26825032.

7: Gonzalez-Serna A, Genebat M, Ruiz-Mateos E, Leal M. Short-term maraviroc 
exposure, a clinical approach to decide on maraviroc prescription in 
HIV-1-infected treatment-naïve patients. Drug Des Devel Ther. 2016 Jan 
18;10:353-6. doi: 10.2147/DDDT.S100639. eCollection 2016. PubMed PMID: 26848259; 
PubMed Central PMCID: PMC4723024.

8: Ball C, Sudhanva M, Jarosz J, Post FA, Hamlyn E. Is there a role for maraviroc 
to treat HIV-associated central nervous system white matter disease? AIDS. 2016 
Jan;30(2):334-6. doi: 10.1097/QAD.0000000000000954. PubMed PMID: 26684826.

9: Blanco JR, Ochoa-Callejero L. Off-label use of maraviroc in clinical practice. 
Expert Rev Anti Infect Ther. 2016 Jan;14(1):5-8. doi: 
10.1586/14787210.2016.1100535. Epub 2015 Oct 28. PubMed PMID: 26509356.

10: Latinovic OS, Zhang J, Tagaya Y, DeVico AL, Fouts TR, Schneider K, Lakowicz 
JR, Heredia A, Redfield RR. Synergistic Inhibition of R5 HIV-1 by the Fusion 
Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for 
Prevention and Treatment. Curr HIV Res. 2016;14(1):24-36. PubMed PMID: 26354735.

11: Pozo-Balado MM, Rosado-Sánchez I, Méndez-Lagares G, Rodríguez-Méndez MM, 
Ruiz-Mateos E, Benhnia MR, Muñoz-Fernández MA, Leal M, Pacheco YM. Maraviroc 
contributes to the restoration of the homeostasis of regulatory T-cell subsets in 
antiretroviral-naive HIV-infected subjects. Clin Microbiol Infect. 2016 Jan 22. 
pii: S1198-743X(16)00018-5. doi: 10.1016/j.cmi.2015.12.025. [Epub ahead of print] 
PubMed PMID: 26806257.

12: Fletcher P, Herrera C, Armanasco N, Nuttall J, Shattock RJ. Limited 
Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues. AIDS Res Hum Retroviruses. 
2016 Jan 29. [Epub ahead of print] PubMed PMID: 26711323.

13: van Lelyveld SF, Symons J, van Ham P, Connell BJ, Nijhuis M, Wensing AM, 
Hoepelman AI. Clinical outcome of maraviroc-containing therapy in heavily 
pre-treated HIV-1-infected patients. Int J Antimicrob Agents. 2016 
Jan;47(1):84-90. doi: 10.1016/j.ijantimicag.2015.09.013. Epub 2015 Oct 25. PubMed 
PMID: 26585497.

14: Kwiatkowski K, Piotrowska A, Rojewska E, Makuch W, Jurga A, Slusarczyk J, 
Trojan E, Basta-Kaim A, Mika J. Beneficial properties of maraviroc on neuropathic 
pain development and opioid effectiveness in rats. Prog Neuropsychopharmacol Biol 
Psychiatry. 2016 Jan 4;64:68-78. doi: 10.1016/j.pnpbp.2015.07.005. Epub 2015 Jul 
16. PubMed PMID: 26190414.

15: Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, Singer J, Pankovich 
J, Laeyendecker O, Kaul R, Kandel G, Kovacs C. Intensifying Antiretroviral 
Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus 
(HIV) Infection Does Not Accelerate HIV Reservoir Reduction. Open Forum Infect 
Dis. 2015 Sep 22;2(4):ofv138. doi: 10.1093/ofid/ofv138. eCollection 2015 Dec. 
PubMed PMID: 26512359; PubMed Central PMCID: PMC4621663.

16: Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, 
Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, 
Marcelin AG; ROCnRAL ANRS-157 Study Group. Virological factors associated with 
outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). J Antimicrob 
Chemother. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280. Epub 2015 Sep 22. 
PubMed PMID: 26396157.

17: Council OD, Swanson MD, Spagnuolo RA, Wahl A, Garcia JV. Role of Semen on 
Vaginal HIV-1 Transmission and Maraviroc Protection. Antimicrob Agents Chemother. 
2015 Dec;59(12):7847-51. doi: 10.1128/AAC.01496-15. Epub 2015 Sep 21. PubMed 
PMID: 26392489; PubMed Central PMCID: PMC4649249.

18: Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, 
Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W. Protection 
Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in 
Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. J Infect 
Dis. 2015 Dec 15;212(12):1988-95. doi: 10.1093/infdis/jiv334. Epub 2015 Jun 12. 
PubMed PMID: 26071566; PubMed Central PMCID: PMC4655858.

19: Jiang X, Feyertag F, Meehan CJ, McCormack GP, Travers SA, Craig C, Westby M, 
Lewis M, Robertson DL. Characterizing the Diverse Mutational Pathways Associated 
with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 
Coreceptor. J Virol. 2015 Nov;89(22):11457-72. doi: 10.1128/JVI.01384-15. Epub 
2015 Sep 2. PubMed PMID: 26339063; PubMed Central PMCID: PMC4645647.

20: Dezzutti CS, Yandura S, Wang L, Moncla B, Teeple EA, Devlin B, Nuttall J, 
Brown ER, Rohan LC. Pharmacodynamic Activity of Dapivirine and Maraviroc Single 
Entity and Combination Topical Gels for HIV-1 Prevention. Pharm Res. 2015 
Nov;32(11):3768-81. doi: 10.1007/s11095-015-1738-7. Epub 2015 Jun 16. PubMed 
PMID: 26078001; PubMed Central PMCID: PMC4600024.